Genmab A/S
NASDAQ:GMABBiotechnology
-$0.12 today
- Market cap
- $31.43B
- Beta
- 0.68
- P/E (TTM)
- 18.7
- EPS (TTM)
- $13.36
Volume 2.96M
Average 1.85M
GMAB Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Genmab A/SNASDAQ: GMAB
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables outflow grows to $0
Q2 FY2026 accounts payables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts payables was $37.17M. Over 3 fiscal years it compounded at +12.3% a year.
Context
- Accounts payables amounted to 10.8% of revenue in FY2025, up 10.8 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $9.29M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
Mixed currencies · from the cash flow
- Latest · FY2025
- 400.32M USD
- Year-over-year change
- —
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 400.32M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 622M | +119.8% |
| FY2022 | 2022-12-31 | 283M | -6.9% |
| FY2021 | 2021-12-31 | 304M | — |
Accounts Payables vs competitors
How GMAB compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Accounts payables amounts to 0.9% of revenue for GMAB, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €834.85M EUR | -430.3% | — | 31.6% | |
| LTM Jun 2026 | $37.17M USD | — | +12.3% | 0.9% | |
| LTM Jun 2026 | $34.69M USD | -48.5% | -60.4% | 0.6% | |
| LTM Sep 2026 | $26.31M USD | -138.8% | -15.0% | 1.9% | |
| LTM Mar 2026 | $10.3M USD | -925.0% | — | 13.0% | |
| LTM Jul 2026 | $8.01M USD | -69.6% | — | 0.3% | |
| LTM Jun 2026 | $5M USD | -66.7% | +44.2% | 4.3% | |
| LTM Sep 2026 | $3.74M USD | -50.2% | — | 1.0% | |
| LTM Mar 2026 | $2.31M USD | -48.2% | -70.5% | 1.5% | |
| LTM Mar 2026 | $233K USD | -91.2% | -54.6% | — | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding GMAB) | — | -69.6% | -54.6% | 1.5% | |
Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · DKK | FY2022 Dec 2022 · DKK | FY2023 Dec 2023 · DKK | FY2024 Dec 2024 · DKK | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | 3.98B | 7.04B | 5.64B | 7.84B | 963.76M |
| Depreciation & Amortization | 248.99M | 362M | 293.62M | 413M | 71.06M |
| Deferred Income Tax | (546M) | 0 | 122M | 0 | 0 |
| Stock-Based Compensation | 310M | 439M | 586M | 721M | 0 |
| Change in Working Capital | (770M) | (1.93B) | 1.36B | (1.6B) | 225.18M |
| Accounts Receivables | (1.07B) | (2.12B) | 797M | (1.59B) | (166.13M) |
| Inventory | 0 | 0 | (57M) | (5M) | (9.01M) |
| Accounts Payables | 304M | 283M | 622M | 0 | 400.32M |
| Other Working Capital | 0 | (90M) | 0 | 0 | 0 |
| Other Non-Cash Items | (997.99M) | (1.99B) | (620.62M) | 388M | (73.06M) |
| Operating Cash Flow | 2.23B | 3.91B | 7.38B | 7.77B | 1.19B |
| Capital Expenditures | (252M) | (317M) | (376M) | (187M) | (37.03M) |
| Acquisitions (Net) | 709M | 2.44B | 0 | (12.25B) | (7.22B) |
| Purchases of Investments | (15.62B) | (9.7B) | (10.91B) | (8.64B) | (995.78M) |
| Sales of Investments | 14.91B | 7.25B | 10B | 11.28B | 2.62B |
| Other Investing Activities | (709M) | (2.44B) | (10M) | (117M) | 0 |
| Investing Cash Flow | (961M) | (2.76B) | (1.28B) | (9.91B) | (5.65B) |
| Debt Repayment | (58M) | (73M) | (91M) | (60M) | 5.23B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 23.02M |
| Common Stock Repurchased | (447M) | (908M) | (564M) | (3.99B) | (430.34M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 85M | 192M | 49M | 129M | (31.02M) |
| Financing Cash Flow | (420M) | (789M) | (606M) | (3.92B) | 4.79B |
| Effect of Forex Changes | 850M | 574M | (518M) | 1.05B | 13.06M |
| Net Change in Cash | 1.7B | 936M | 4.97B | (5.01B) | 345.33M |
| Free Cash Flow | 1.98B | 3.6B | 7B | 7.58B | 1.15B |
Genmab A/S
NASDAQ:GMAB
Intrinsic Alpha fair value
Locked
Current Price
$50.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.